BMY vs UFPT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BMY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and UFPT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and UFPT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.

Full BMY guide

UFP Technologies, Inc. is a contract development and manufacturing organization headquartered in Newburyport, Massachusetts, incorporated in Delaware in 1993 and listed on Nasdaq as UFPT. It engineers and manufactures single-use and single-patient medical devices, components and packaging that customers sell under their own labels: protective drapes for robotic surgery, surgical and endoscopic disposables, advanced wound care and infection prevention products, packaging for orthopedic implants, cardiac implant components and catheter dispenser coils. The work runs through die cutting, molding, thermoforming, welding and lamination under trademarks including UFP MEDTECH, FLEXSHIELD and BIOSHELL. The company had ~4,846 full-time employees as of January 2026, up from ~4,146 a year earlier, across plants in the United States, Puerto Rico, the Dominican Republic, Mexico, Ireland and Costa Rica; nineteen sites are ISO 13485 certified and thirteen are FDA registered. Medical customers supplied ~92.1% of 2025 net sales.

Full UFPT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BMY drivers: New product portfolio ramp; Oncology and immunology depth.
• UFPT drivers: The Intuitive Surgical contract, now written through 2029; Shifting production to the Dominican Republic and Mexico.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For UFPT, customer concentration is the first-order risk: two customers accounted for approximately ~24.3% and ~21.5% of 2025 net sales, and the company's own risk factors flag the possibility that Intuitive Surgical could decide to manufacture the products itself or through another supplier.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; UFPT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and UFPT guides.

BMY. Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.

UFPT. At about ~$304 per share on ~7.75 million shares outstanding, UFPT carries a market value near ~$2.36 billion, which is roughly ~33 times trailing earnings and roughly ~3.7 times trailing revenue. That is a premium to most contract manufacturers, reflecting the medical mix, the ~29% gross margin and a multi-year record of double-digit growth. The balance sheet is light, with ~$117 million of long-term debt against a ~$275 million facility maturing in June 2029.

Headline figures (approximate, early 2026): BMY shows revenue (ttm) ~$48 billion, operating margin ~20% (varies with acquisition charges), net income (ttm) volatile, pressured by large acquisition write-offs, dividend yield ~4-5%; UFPT shows revenue (ttm) ~$632M, fy2025 revenue ~$603M (up ~19.5% YoY), q2 2026 revenue ~$174.0M (up ~15.1% YoY, ~12.4% organic), net income (ttm) ~$72M, diluted EPS ~$9.25.

BMY and UFPT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and UFPT exposure against your real portfolio. It is not an investment adviser.